Evgen Pharma (GB:TCF) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TheraCryf plc has been awarded a European patent for its highly selective Orexin 1 receptor antagonist, a promising development in treatments for mental health conditions like anxiety and addiction. The patent enhances TheraCryf’s international intellectual property portfolio, supporting its strategy to partner with larger pharmaceutical companies for advanced trials and commercialization. This milestone could attract investors looking to capitalize on the company’s innovative neuropsychiatry and oncology pipeline.
For further insights into GB:TCF stock, check out TipRanks’ Stock Analysis page.